Tagged Content
Tags > Medication Updates
Year:
Medication:
Abilify (aripiprazole)
Addyi
Antipsychotics
Aripiprazole
Aristada
Belsomra
Brintellix
Buprenorphine and naloxone
Probuphine
Clozapine
Clozapine REMS
Chantix and Zyban
Cymbalta
Daytrana
Diazepam
Effexor
Farxiga
Fentanyl and Opioids
Geodon
Hysingla ER
Ingrezza
Ketamine
Lamictal (lamotrigine)
Lorazepam
Lucemyra (lofexidine hydrochloride)
Lunesta
Methylphenidate
Naloxone
Naloxone/Evzio
Naltrexone
Olanzapine
Olanzapine/Zyprexa
Opana ER
Opioids
UPDATE: Opioids
Opioids and Benzodiazepines
UPDATE: Opioids and Benzodiazepines
Rexulti
Spravato (Esketamine)
Strattera
Sublocade
Tanzeum
Targiniq ER
Tramadol
Treatment for Alcohol Use Disorder
Vraylar
Vynase
Ziprasidone
Zolpidem
Zyprexa
General Resources:
DEA Pharmacists' Manual
FDA Medication Updates
NIMH Mental Health Medications Guide
2020
FDA requiring labeling changes for opioid pain medicines and opioid use disorder medicines regarding Naloxone with a goal to help reduce opioid overdoses and deaths.
2019
Ketamine Infusion Therapy Resource
This checklist provides considerations for prescribing or providing care to persons undergoing ketamine infusion therapy.
FDA releases updated Drug Safety Communication about Opioids
The update reinforces that individuals who are physically dependent on opioids may experience serious harm if their medications are suddenly discontinued or their dose is rapidly decreased.
View all tags